Toronto · Independent Shariah screening · Screened October 1, 2026

TSX Shariah screener · October 2026

BioSyent Inc.

RX · TSXV · Healthcare

PASS

Is BioSyent Inc. (RX) Halal?

Debt ÷ market cap 1.1% / 33%
Non-compliant income 0.5% / 5%

BioSyent Inc. · TSX Venture: RX · Healthcare

Price chart by TradingView · Market data may be delayed · Shown for information only — not investment advice.

The short answer

BioSyent Inc. (TSX Venture: RX) is a PASS. The business gate passes: it is a Mississauga specialty healthcare company that in-licenses, acquires, markets, and distributes pharmaceutical and oral-health products (FeraMAX, Tibella, Inofolic, RepaGyn, plus the Oral Science dental business acquired March 1, 2026), with no prohibited segments. The debt gate passes: short-term debt of C$2.0M (June 30, 2026) is about 1.1% of the ~C$189.8M market cap (11,308,835 shares × C$16.78, October 1, 2026), far under the ~33% ceiling. The income gate passes: separately disclosed interest income of C$94,412 is about 0.5% of Q2 2026 net revenues of C$19,872,763, well under the ~5% ceiling (H1 basis ~0.8%). Cash, equivalents, short-term and long-term investments total ~C$12.2M, about 6.4% of market cap. No Zoya, Musaffa, or ShariaPortfolio coverage was found. This is a rules-based screen, not a religious ruling.

Gate 1 — Business activity: PASS

BioSyent is a profitable, growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing, and distributing pharmaceutical and oral-health products in Canada and internationally. Its pharmaceutical business sells FeraMAX (iron deficiency anemia), Tibella/Tibelia (tibolone HRT), Inofolic (natural health product for PCOS), RepaGyn, Gelclair (oral mucositis), Cathejell, Combogesic, and Proktis-M; the oral-health business is Oral Science Inc. (Brossard, QC), acquired March 1, 2026, contributing Q2 2026 sales of C$8.2M in its first full quarter; a small legacy insecticide segment (C$0.54M in Q2) sells pest-control insecticides. There are no alcohol, gambling, weapons, tobacco, cannabis, conventional-lending/insurance, or pork segments. The business gate passes.

Gate 2 — Debt and cash: PASS

At June 30, 2026 (Q2 2026 interim financial statements, released August 20, 2026), interest-bearing debt was C$2.0M — short-term debt only, the residual of the C$8M of RBC facilities drawn for the March 2026 Oral Science acquisition (C$6M one-year term loan plus C$2M revolver), mostly repaid in H1 2026; non-current liabilities of C$820k are mostly lease and related items. Against a market cap of ~C$189.8M (11,308,835 shares outstanding × C$16.78, October 1, 2026, TSX Venture), that is about 1.1% — far under the ~33% ceiling; about 1.5% including the non-current liabilities, also a pass, so the result is robust to debt treatment. The company paid a quarterly dividend of C$0.055/share (March 13 and June 15, 2026; September 15, 2026 declared) and repurchased 218,500 shares in H1 2026. Cash, cash equivalents and short-term investments of C$8.94M plus long-term investments of C$3.29M total ~C$12.2M, about 6.4% of market cap. The debt and cash gates pass.

Gate 3 — Non-compliant income: PASS

The Q2 2026 financial statements separately disclose interest income of C$94,412 (shown as its own line in the EBITDA reconciliation, not netted away; C$261,204 in H1 2026). Against Q2 2026 net revenues of C$19,872,763, that is about 0.5% — well under the ~5% ceiling (H1 basis ~0.8%). The income gate passes.

BDS screen

Whether this company appears on boycott, divestment and sanctions (BDS) lists. Informational only — it does not change the Shariah screening result above, and it is not a religious ruling.

No BDS listing found on the BDS movement's published boycott, divestment, or pressure lists (checked October 2026).

Moral screen

Beyond the Shariah financial gates, this checks the company’s documented business ties to the Israeli and US militaries, and to weapons manufacturing. Every finding is factual and sourced. A row with no finding means none surfaced in our review — not proof of none.

Israeli military business
No findings published.
US military business
No findings published.
Weapons manufacturing & arms trade
No findings published.

Key figures used

Frequently asked questions

Is BioSyent (RX) halal?

Our October 2026 screen gives BioSyent Inc. (TSX Venture: RX) a PASS. The business gate passes (Mississauga specialty healthcare company that in-licenses, acquires, markets, and distributes pharmaceutical and oral-health products — FeraMAX, Tibella, Inofolic, RepaGyn, plus the Oral Science dental business acquired March 1, 2026; no prohibited segments). The debt gate passes (short-term debt of C$2.0M at June 30, 2026 is about 1.1% of the ~C$189.8M market cap, far under the ~33% ceiling). The income gate passes (separately disclosed interest income of C$94,412 is about 0.5% of Q2 2026 net revenues of C$19,872,763, well under the ~5% ceiling; H1 basis ~0.8%). Cash, equivalents, short-term and long-term investments total ~C$12.2M, about 6.4% of market cap. No Zoya, Musaffa, or ShariaPortfolio coverage was found. This is a rules-based screen, not a religious ruling.

What does BioSyent do?

BioSyent is a profitable, growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing, and distributing pharmaceutical and oral-health products in Canada and internationally. Its pharmaceutical business sells FeraMAX (iron deficiency anemia), Tibella/Tibelia (tibolone HRT), Inofolic (natural health product for PCOS), RepaGyn, Gelclair (oral mucositis), Cathejell, Combogesic, and Proktis-M. Its oral-health business is Oral Science Inc. of Brossard, QC, acquired March 1, 2026, which contributed C$8.2M of sales in Q2 2026, its first full quarter. A small legacy insecticide segment (C$0.54M in Q2 2026) sells pest-control insecticides.

How much debt does BioSyent have?

At June 30, 2026 (Q2 2026 interim financial statements, released August 20, 2026), interest-bearing debt was C$2.0M — short-term debt only, the residual of the C$8M of RBC facilities drawn for the March 2026 Oral Science acquisition (C$6M one-year term loan plus C$2M revolver), mostly repaid in H1 2026. Against a market cap of ~C$189.8M (11,308,835 shares outstanding × C$16.78, October 1, 2026, TSX Venture), that is about 1.1% — far under the ~33% ceiling (about 1.5% including C$820k of non-current liabilities, also a pass). The company pays a quarterly dividend of C$0.055/share and repurchased 218,500 shares in H1 2026.

Is BioSyent’s income compliant?

Yes. The Q2 2026 financial statements separately disclose interest income of C$94,412 (its own line in the EBITDA reconciliation, not netted away; C$261,204 in H1 2026). Against Q2 2026 net revenues of C$19,872,763, that is about 0.5% — well under the ~5% ceiling (H1 basis ~0.8%). The income gate passes.

What do third-party Shariah screeners say about RX?

No Zoya, Musaffa, or ShariaPortfolio rating was found for RX in public search — none of the three named providers surfaced coverage, so no rating is claimed here.

Sources

Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.